Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Rituximab in Chronic Cold Agglutinin Disease
NCT02689986Phase 2Completed
- Sponsor
- Helse Fonna
- Start
- Jan 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in cold agglutinin disease (CAD), sponsored by Helse Fonna. Primary endpoint: Overall Response Rate at 6 months. Started Jan 2013; status: completed.
02
Drugs
bendamustine
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT02689986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689986.